Literature DB >> 25438811

Whole-brain radiotherapy in patients with brain metastases from melanoma.

Macarena de la Fuente1, Kathryn Beal, Richard Carvajal, Thomas J Kaley.   

Abstract

AIMS: To describe results of melanoma brain metastases (BM) treated with whole-brain radiation (WBRT).
METHODS: Retrospective review of patients with melanoma BM treated with WBRT divided into two groups based on the timing of WBRT (at BM diagnosis or recurrence).
RESULTS: We identified 61 patients with melanoma BM who received WBRT. For the group treated at diagnosis (n = 39): median overall survival was 3 months; best radiographic response included one partial response, ten stable disease, 18 progressive disease, and ten no follow-up imaging. For the group treated at recurrence (n = 22): median overall survival was 3 months; best radiographic response was three partial response, four stable disease, eight progressive disease, and seven no follow-up imaging.
CONCLUSION: WBRT activity was limited; however, its role in symptom palliation is unclear.

Entities:  

Keywords:  WBRT; brain metastases; ipilimumab; melanoma; overall survival; radiographic response

Mesh:

Year:  2014        PMID: 25438811      PMCID: PMC6113948          DOI: 10.2217/cns.14.40

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  20 in total

1.  A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

Authors:  D F McDermott; J W Mier; D P Lawrence; M R van den Brink; M A Clancy; K M Rubin; M B Atkins
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

2.  Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases.

Authors:  J Ellerhorst; E Strom; E Nardone; I McCutcheon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-01-01       Impact factor: 7.038

3.  A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.

Authors:  Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

4.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

5.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

Authors:  J H Sampson; J H Carter; A H Friedman; H F Seigler
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

Review 6.  Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Authors:  Jason J Luke; F Stephen Hodi
Journal:  Oncologist       Date:  2013-05-24

7.  Determinants of outcome in melanoma patients with cerebral metastases.

Authors:  K M Fife; M H Colman; G N Stevens; I C Firth; D Moon; K F Shannon; R Harman; K Petersen-Schaefer; A C Zacest; M Besser; G W Milton; W H McCarthy; J F Thompson
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

Review 8.  Multimodality management of brain metastases in metastatic melanoma patients.

Authors:  Wolfram E Samlowski; Randy L Jensen; Dennis C Shrieve
Journal:  Expert Rev Anticancer Ther       Date:  2007-12       Impact factor: 4.512

9.  Metastatic melanoma to the brain: surgery and radiation is still the standard of care.

Authors:  Sarah Nicholas; Dimitrios Mathios; Christopher Jackson; Michael Lim
Journal:  Curr Treat Options Oncol       Date:  2013-06

10.  Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma.

Authors:  Henrik Hauswald; Jan-Oliver Dittmar; Daniel Habermehl; Stefan Rieken; Florian Sterzing; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2012-08-02       Impact factor: 3.481

View more
  5 in total

1.  Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Authors:  Cara L Haymaker; DaeWon Kim; Marc Uemura; Luis M Vence; Ann Phillip; Natalie McQuail; Paul D Brown; Irina Fernandez; Courtney W Hudgens; Caitlin Creasy; Wen-Jen Hwu; Padmanee Sharma; Michael T Tetzlaff; James P Allison; Patrick Hwu; Chantale Bernatchez; Adi Diab
Journal:  Cancer Immunol Res       Date:  2017-01-06       Impact factor: 11.151

Review 2.  The Treatment of Melanoma Brain Metastases.

Authors:  Nour Kibbi; Harriet Kluger
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 3.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

4.  Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.

Authors:  Cecilia Jiang; Troy J Kleber; Jeffrey M Switchenko; Mohammad K Khan
Journal:  Radiat Oncol       Date:  2021-02-08       Impact factor: 3.481

Review 5.  Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.

Authors:  Marvin Kuske; Ricarda Rauschenberg; Marlene Garzarolli; Michelle Meredyth-Stewart; Stefan Beissert; Esther G C Troost; Oliva Isabella Claudia Glitza; Friedegund Meier
Journal:  Am J Clin Dermatol       Date:  2018-08       Impact factor: 7.403

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.